Young Blood and Plasma Transfusions

Young Blood and Plasma Transfusions

The FDA recently warned that plasma infusions from young people provides “no proven clinical benefit” against normal aging, Alzheimer’s disease, or a host of other diseases. 

Directors Gottlieb and Marks from the Center for Biologics Evaluation and Research say young-blood transfusions can pose risks.

Most research thus far into young-blood transfusions has been conducted in mice. Some of the mouse studies have been encouraging, but other studies have been less encouraging. One biotech company is currently testing a plasma-derived product in Alzheimer’s patients; a previous study from the company yielded mixed results.

One startup company with locations in Los Angeles, San Francisco, Houston, Tampa, Fla., and Omaha, Neb was selling young-blood transfusions at a cost of $8,000 for 1 liter of young blood, or $12,000 for 2 liters. Following a statement released by the FDA regarding young-blood, a notice on the companies site said it would no longer offer the transfusions.

The FDA says the only context in which consumers should consider pursuing young-blood transfusion therapy is within mainstream clinical trials.

Comment: Ponce de León was supposedly searching for the Fountain of Youth, yet there is no contemporary evidence to support the story, which all modern historians call a myth. And yet today, we are still pursuing the fountain of youth. Will this also be called a myth?

Share this post:

Comments on "Young Blood and Plasma Transfusions"

Comments 0-5 of 0

Please login to comment